These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1627393)
21. [A novel paradigm and new targets in cancer therapy]. Novik AA; Kamilova TA; Tsygan VN Vopr Onkol; 2003; 49(6):695-704. PubMed ID: 14976912 [No Abstract] [Full Text] [Related]
22. [The "antisense" strategy: a new approach in the development of antineoplastic substances and gene therapy]. Hélène C J Pharm Belg; 1997; 52(2):79-85. PubMed ID: 9296958 [No Abstract] [Full Text] [Related]
23. Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Sawyers CL; Sausville EA Curr Opin Investig Drugs; 2002 Mar; 3(3):478-81. PubMed ID: 12054100 [No Abstract] [Full Text] [Related]
24. Overview. A new discovery phase for antitumor drugs? Gewirtz DA Curr Opin Investig Drugs; 2000 Dec; 1(4):508-10. PubMed ID: 11249706 [No Abstract] [Full Text] [Related]
25. QC in antisense oligo synthesis. Agris PF; Smith S; Fu C; Simkins SG Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500 [No Abstract] [Full Text] [Related]
26. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Takimoto CH Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662 [No Abstract] [Full Text] [Related]
27. Environmental protection: studies highlight importance of tumor microenvironment. Hede K J Natl Cancer Inst; 2004 Aug; 96(15):1120-1. PubMed ID: 15292379 [No Abstract] [Full Text] [Related]
28. Current status of cancer drug development: failure or limited success? Grindey GB Cancer Cells; 1990 Jun; 2(6):163-71. PubMed ID: 2201343 [TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide technology in the development of cancer therapeutics. Tseng BY; Brown KD Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240 [No Abstract] [Full Text] [Related]
30. Target selection issues in drug discovery and development. Sausville EA J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602 [TBL] [Abstract][Full Text] [Related]
32. New approach to targeted prodrug therapy. Brown H Lancet Oncol; 2002 Dec; 3(12):715. PubMed ID: 12473507 [No Abstract] [Full Text] [Related]
33. Special report: pharmacogenomics of cancer-candidate genes. Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(5):1-3. PubMed ID: 18080403 [No Abstract] [Full Text] [Related]
34. Use of healthy volunteers drives clinical oncology drug development decision making. Iwamoto M; Iannone R; Wagner JA Clin Pharmacol Ther; 2012 Nov; 92(5):571-4. PubMed ID: 23010649 [No Abstract] [Full Text] [Related]
35. Introduction: new anticancer drug design and discovery based on advances in molecular oncology. Workman P Semin Cancer Biol; 1992 Dec; 3(6):329-33. PubMed ID: 1286153 [No Abstract] [Full Text] [Related]
36. RNA-based therapy unlocks drugs within cancer cells. Erdmann J J Natl Cancer Inst; 2002 Dec; 94(24):1829-30. PubMed ID: 12488474 [No Abstract] [Full Text] [Related]
37. A modeling and simulation framework to support early clinical drug development decisions in oncology. Bruno R; Lu JF; Sun YN; Claret L J Clin Pharmacol; 2011 Jan; 51(1):6-8. PubMed ID: 20628172 [No Abstract] [Full Text] [Related]
38. Detection and management of oncology drug interactions: Can we do better? Chan A; Yap KY Maturitas; 2010 Mar; 65(3):181-2. PubMed ID: 20036470 [No Abstract] [Full Text] [Related]
39. Integrating genetic approaches into the discovery of anticancer drugs. Hartwell LH; Szankasi P; Roberts CJ; Murray AW; Friend SH Science; 1997 Nov; 278(5340):1064-8. PubMed ID: 9353181 [TBL] [Abstract][Full Text] [Related]
40. Phospholipid antitumor agents. Houlihan WJ; Lohmeyer M; Workman P; Cheon SH Med Res Rev; 1995 May; 15(3):157-223. PubMed ID: 7658750 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]